Back to Report Store Home

Global Women’s Health Drugs Market to 2024 – Influx of New Products Including Orilissa, Relugolix and Bremelanotide to Diversify Landscape and Drive Growth

  • Published: Jan-2019
  • Report Code: GBIHC488MR
  • Report Format: pdf

Description

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Introduction

2.1 Therapy Area Overview

2.1.1 Endometriosis

2.1.2 Polycystic Ovarin Syndrome

2.1.3 Cervical Intraepithelial Neoplasia

2.1.4 Menopausal Disorders

2.1.5 Infertility

2.2 Symptoms

2.2.1 Endometriosis

2.2.2 Polycystic Ovarian Syndrome

2.2.3 Cervical Intraepithelial Neoplasia

2.2.4 Menopausal Disorders

2.2.5 Infertility

2.3 Diagnosis

2.3.1 Endometriosis

2.3.2 Polycystic Ovarian Syndrome

2.3.3 Cervical Intraepithelial Neoplasia

2.3.4 Menopausal Disorders

2.3.5 Infertility

2.4 Etiology and Epidemiology

2.4.1 Endometriosis

2.4.2 Polycystic Ovarian Syndrome

2.4.3 Cervical Intraepithelial Neoplasia

2.4.4 Menopause

2.4.5 Infertility

2.5 Pathophysiology

2.5.1 Endometriosis

2.5.2 Polycystic Ovarian Syndrome

2.5.3 Cervical Intraepithelial Neoplasia

2.6 Co-morbidities and Complications

2.6.1 Endometriosis

2.6.2 Polycystic Ovarian Syndrome

2.6.3 Cervical Intraepithelial Neoplasia

2.6.4 Menopause and Menopausal Disorders

2.6.5 Infertility

2.7 Treatment

2.7.1 Treatment Options

3 Key Marketed Products

3.1 Overview

3.2 Premarin family (conjugated estrogens) – Pfizer

3.3 Lupron/Lupron Depot (leuprolide acetate SR) - AbbVie

3.4 Gonal-F (follitropin alfa) - Merck KGaA

3.5 Mirena (levonorgestrel) - Bayer

3.6 Celebrex (celecoxib) - Pfizer

3.7 Implanon/Nexplanon (etonogestrel) - Merck & Co.

3.8 Yasmin/Yaz (drospirenone and ethinylestradiol) - Bayer

3.9 Nuvaring (ethinylestradiol and etonogestrel) - Merck & Co

3.1 Gardasil – Merck and Co

3.11 Esmya (ulipristal acetate) – Gedoen Richter/Allergan

3.12 Orilissa (elagolix sodium) – AbbVie

4 Pipeline Landscape Assessment

4.1 Overview

4.2 Pipeline Development Landscape

4.3 Molecular Targets in the Pipeline

4.4 Clinical Trials Landscape

4.4.1 Clinical Trial Failure Rates

4.4.2 Clinical Trial Duration

4.4.3 Clinical Trial Size

4.4.4 Cumulative Clinical Trial Size

4.5 Assessment of Key Pipeline Products

4.5.1 Relugolix – Takeda Pharmaceutical Co. Ltd

4.5.2 Bremelanotide – AMAG Pharmaceuticals Inc

4.5.3 SAGE-217 – Sage Therapeutics Inc.

4.5.4 Fezolinetant – Ogeda SA

4.5.5 Zulresso – Sage Therapeutics

4.5.6 Bizalimogene Ralaplasmid + Mavilimogene Ralaplasmid - Inovio Pharmaceuticals Inc

4.5.7 Retosiban – GlaxoSmithKline

5 Multi-scenario Market Forecast to 2024

5.1 Overall Market Size

5.2 Generic Penetration

5.3 Revenue Forecast by Molecular Target Class

5.3.1 G Protein-Coupled Receptor

5.3.2 Nuclear Receptor

5.3.3 Pathogen

5.3.4 Ion Channels/Transporter

6 Company Analysis and Positioning

6.1 Revenue and Market Share Analysis by Company

6.1.1 Bayer AG – Company to Remain a Market Leader within Women’s Health

6.1.2 AbbVie Inc – Orilissa to Reach Blockbuster Status, Boosting Company’s Market Share

6.1.3 Allergan – Revenue Gains From Fibristal, Lo Loestrin Fe and Liletta to Offset Losses from Minastrin 24 Fe and Estrace

6.1.4 Merck & Co. – Company to Remain a Key Player Due to Growth of Gardasil/Gardasil 9

6.1.5 GlaxoSmithKline – Cervarix and Retosiban to Drive Strong Growth

6.1.6 Pfizer – How will patent expiration affect revenues for women’s health market?

6.1.7 TherapeuticsMD – Women’s Health Specialist to Gain Considerable Market Share by 2024

6.2 Company Landscape

6.3 Marketed and Pipeline Portfolio Analysis

7 Strategic Consolidations

7.1 Licensing Deals

7.1.1 Deals by Region, Value and Year

7.1.2 Deals by Key Indication

7.1.3 Deals by Stage of Development and Value

7.1.4 Deals by Molecule Type, Molecular Target and Value

7.1.5 Licensing Deals with Disclosed Values

7.2 Co-development Deals

7.2.1 Deals by Region, Value and Year

7.2.2 Deals by Key Indication

7.2.3 Deals by Stage of Development and Value

7.2.4 Deals by Molecule Type, Molecular Target and Value

7.2.5 Co-development Deals with Disclosed Values

8 Appendix

8.1 References

8.2 Abbreivations

8.3 List of All Pipeline Products

8.4 Disease List

8.5 Methodology

8.5.1 Coverage

8.5.2 Secondary Research

8.5.3 Market Size and Revenue Forecasts

8.5.4 Pipeline Analysis

8.5.5 Competitive Landscape

8.6 Contact Us

8.7 Disclaimer

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$4995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$9990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$14985
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards